Navigation Links
Predicting how patients respond to therapy
Date:9/6/2012

CAMBRIDGE, MA -- A new study led by MIT neuroscientists has found that brain scans of patients with social anxiety disorder can help predict whether they will benefit from cognitive behavioral therapy.

Social anxiety is usually treated with either cognitive behavioral therapy or medications. However, it is currently impossible to predict which treatment will work best for a particular patient. The team of researchers from MIT, Boston University (BU) and Massachusetts General Hospital (MGH) found that the effectiveness of therapy could be predicted by measuring patients' brain activity as they looked at photos of faces, before the therapy sessions began.

The findings, published this week in the Archives of General Psychiatry, may help doctors choose more effective treatments for social anxiety disorder, which is estimated to affect around 15 million people in the United States.

"Our vision is that some of these measures might direct individuals to treatments that are more likely to work for them," says John Gabrieli, the Grover M. Hermann Professor of Brain and Cognitive Sciences at MIT, a member of the McGovern Institute for Brain Research and senior author of the paper.

Lead authors of the paper are MIT postdoc Oliver Doehrmann and Satrajit Ghosh, a research scientist in the McGovern Institute.

Choosing treatments

Sufferers of social anxiety disorder experience intense fear in social situations that interferes with their ability to function in daily life. Cognitive behavioral therapy aims to change the thought and behavior patterns that lead to anxiety. For social anxiety disorder patients, that might include learning to reverse the belief that others are watching or judging them.

The new paper is part of a larger study that MGH and BU ran recently on cognitive behavioral therapy for social anxiety, led by Mark Pollack, director of the Center for Anxiety and Traumatic Stress Disorders at MGH, and Stefan Hofmann, director of the Social Anxiety Program at BU.

"This was a chance to ask if these brain measures, taken before treatment, would be informative in ways above and beyond what physicians can measure now, and determine who would be responsive to this treatment," Gabrieli says.

Currently doctors might choose a treatment based on factors such as ease of taking pills versus going to therapy, the possibility of drug side effects, or what the patient's insurance will cover. "From a science perspective there's very little evidence about which treatment is optimal for a person," Gabrieli says.

The researchers used functional magnetic resonance imaging (fMRI) to image the brains of patients before and after treatment. There have been many imaging studies showing brain differences between healthy people and patients with neuropsychiatric disorders, but so far imaging has not been established as a way to predict patients' responses to particular treatments.

Measuring brain activity

In the new study, the researchers measured differences in brain activity as patients looked at images of angry or neutral faces. After 12 weeks of cognitive behavioral therapy, patients' social anxiety levels were tested. The researchers found that patients who had shown a greater difference in activity in high-level visual processing areas during the face-response task showed the most improvement after therapy.

Gabrieli says it's unclear why activity in brain regions involved with visual processing would be a good predictor of treatment outcome. One possibility is that patients who benefited more were those whose brains were already adept at segregating different types of experiences, Gabrieli says.

The researchers are now planning a follow-up study to investigate whether brain scans can predict differences in response between cognitive behavioral therapy and drug treatment.

"Right now, all by itself, we're just giving somebody encouraging or discouraging news about the likely outcome" of therapy, Gabrieli says. "The really valuable thing would be if it turns out to be differentially sensitive to different treatment choices."


'/>"/>
Contact: Sarah McDonnell
s_mcd@mit.edu
617-253-8923
Massachusetts Institute of Technology
Source:Eurekalert

Related biology news :

1. Disease-carrying colonizers on the move: Predicting the spread of ticks across Canada
2. Researchers identified a protein useful in predicting the risk of pulmonary metastases in breast cancer patients
3. Discovery of mechanisms predicting response to new treatments in colon cancer
4. Reproductive health providers should discuss environmental exposure risks with patients
5. Low-calorie diet may be harmful for bowel disease patients
6. Interventional radiology: Mitigating symptoms, improving quality of life of MS patients
7. Interventional radiologists see significant symptom relief in MS patients
8. Crestor Delivers Latest LDL-C Targets in High-Risk Patients at Lower Doses than Other Statins
9. Tokai Pharmaceuticals galeterone well-tolerated in patients with advanced prostate cancer
10. Obese patients face higher radiation exposure from CT scans -- but new technology can help
11. Transcatheter aortic valve implantation shows promise in patients with severe aortic stenosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting Medicaid ... setting a new clinical standard in telehealth thanks to ... leveraging the higi platform, IMPOWER patients can routinely track ... and body mass index, and, when they opt in, ... convenient visit to a local retail location at no ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
Breaking Biology News(10 mins):
(Date:4/27/2016)... ... , ... Global Stem Cells Group CEO Benito Novas announced that ... GSCG affiliate Kimera Labs in Miami. , In 2004, Ross received his Ph.D. in ... hematologic disorders and the suppression of graft vs. host disease (GVHD) under UM Professor ...
(Date:4/26/2016)... , ... April 26, 2016 , ... ... announced that Ardy Arianpour has joined the company as Chief Business Officer. Arianpour, ... bringing innovative genomic technologies to market, was most recently Chief Commercial Officer of ...
(Date:4/26/2016)... ... April 26, 2016 , ... BioFactura, Inc ., ... A round of financing. Healthy investor interest drove significant oversubscription of the original ... biologics, known as biosimilars, to the advanced preclinical stages. , Chief Executive Officer and ...
(Date:4/26/2016)... 26, 2016 genae, a Contract ... industries, announced today the appointment of Prof. Dr. Jörn ... Balzer,s responsibilities will include all clinical, safety and risk ... feel privileged and honored with the acceptance of Prof. ... , CEO at genae. "Prof. Balzer,s impressive and extensive ...
Breaking Biology Technology: